R
Roberto A. Leon Ferre
Researcher at Mayo Clinic
Publications - 8
Citations - 529
Roberto A. Leon Ferre is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 321 citations.
Papers
More filters
Journal ArticleDOI
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
Robert D. McBane,Waldemar E. Wysokinski,Jennifer Le-Rademacher,Tyler Zemla,Aneel A. Ashrani,Alfonso Tafur,Usha Perepu,Daniel M. Anderson,Krishna Gundabolu,Charles Kuzma,Juliana Perez Botero,Roberto A. Leon Ferre,Stanislav Henkin,Charles J. Lenz,Damon E. Houghton,Prakash Vishnu,Charles L. Loprinzi +16 more
TL;DR: Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (VTE) and apixaban is approved for the treatment of acute VTE.
Journal ArticleDOI
Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
Robert D. McBane,Charles L. Loprinzi,Aneel A. Ashrani,Juliana Perez Botero,Roberto A. Leon Ferre,Stanislav Henkin,Charles J. Lenz,Jennifer Le-Rademacher,Waldemar E. Wysokinski +8 more
TL;DR: The main aim of the ADAM-VTE trial is to test the hypothesis that apixaban is associated with a significantly lower rate of major bleeding compared to dalteparin in the treatment of cancer patients with acute VTE.
Journal ArticleDOI
Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial
Robert D. McBane,Waldemar E. Wysokinski,Jennifer Le-Rademacher,Aneel A. Ashrani,Alfonso Tafur,Krishna Gundabolu,Juliana Perez-Botero,Usha Perepu,Daniel M. Anderson,Charles Kuzma,Roberto A. Leon Ferre,Stanislav Henkin,Charles J. Lenz,Charles L. Loprinzi +13 more
TL;DR: Oral apixaban therapy was associated with very low rates of bleeding and significantly lower VTE recurrence with superior quality of life outcome measures compared to parenteral dalteparin in the treatment of cancer associated VTE.
Journal ArticleDOI
Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study
Grace Choong,Savannah S Liddell,Roberto A. Leon Ferre,Ciara C. O’Sullivan,Kathryn J. Ruddy,Tufia C. Haddad,Timothy J. Hobday,Prema P. Peethambaram,Minetta C. Liu,Matthew P. Goetz,Karthik V. Giridhar +10 more
TL;DR: The most common post-CDK4/6i treatments were PI3K/mTOR inhibitors, single-agent ET, or chemotherapy, with similar PFS times comparing chemotherapy and ET, with slightly longer PFS for targeted strategies as discussed by the authors .
Journal ArticleDOI
Reply to On the proportion of male breast cancer among all breast cancers.
Siddhartha Yadav,Dhauna Karam,Irbaz Bin Riaz,Hao Xie,Urshila Durani,Narjust Duma,Karthik V. Giridhar,Tina J. Hieken,Judy C. Boughey,Robert W. Mutter,John R. Hawse,Rafael E. Jimenez,Fergus J. Couch,Roberto A. Leon Ferre,Kathryn J. Ruddy +14 more
TL;DR: Investigations into the disparities of geographically based MBC proportions may possibly lead to an insight into its pathogenesis.